Life Matters

Fighting Antibiotic-resistant Bacteria via Biofilm Prevention

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in July 2016 by Amit Elbaz, Prof. Robert S. Marks, Karina Golberg, and Prof. Ariel Kushmaro, Life Matters operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing solutions for antibiotic-resistant bacteria.

Business overview

Life Matters is a preclinical-stage biopharmaceutical company dedicated to combating antibiotic-resistant bacteria, particularly those acquired in hospital settings. The company's core technology involves preventing bacterial biofilm formation, which is a crucial mechanism allowing bacteria to survive environmental stresses and evade immune responses. Its lead product, API, IBF-2, is a compound designed to attenuate the biofilm mode of growth, making infections more treatable. Life Matters targets the global healthcare and life sciences markets, specifically within pharmaceuticals and medical devices, addressing chronic lung infections and other conditions where biofilm-related P. aeruginosa contributes to morbidity and mortality.

Company Intelligence Q&A

What is Life Matters' primary focus?
Life Matters is a preclinical-stage biopharmaceutical company focused on tackling antibiotic-resistant bacteria by preventing their biofilm mode of growth, particularly those acquired in hospitals.
What is the core technology developed by Life Matters?
Life Matters has developed a new solution for fighting resistant bacteria by preventing the bacteria's biofilm mode of growth, which makes infections more treatable. This approach does not create resistance-creating selective pressure.
What is IBF-2?
IBF-2 is Life Matters' lead product, an active pharmaceutical ingredient (API) with an innovative mechanism of action designed to attenuate the biofilm mode of growth, a crucial phenotype that allows bacteria to survive environmental stresses and host immune systems.
Which markets does Life Matters target?
Life Matters targets global markets within the healthcare and life sciences sectors, focusing on pharmaceuticals and medical devices to address issues related to antibiotic-resistant bacteria and chronic lung infections.
When was Life Matters founded and by whom?
Life Matters was founded in July 2016 by Amit Elbaz, Prof. Robert S. Marks, Karina Golberg, and Prof. Ariel Kushmaro.

External links